Phase III Enrollment For Amgen's Panitumumab Slowed By Erbitux Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in Amgen's U.S. Phase III trial for the colon cancer agent panitumumab has substantially slowed since the launch of Bristol-Myers Squibb/ImClone's Erbitux (cetuximab)
You may also be interested in...
Amgen To File Panitumumab In Second-Half 2005
Application will seek approval for third-line treatment of colorectal cancer. Amgen says the anti-EGRF monoclonal antibody shows fewer adverse reactions than Bristol-Myers Squibb/Imclone's Erbitux.
Amgen To File Panitumumab In Second-Half 2005
Application will seek approval for third-line treatment of colorectal cancer. Amgen says the anti-EGRF monoclonal antibody shows fewer adverse reactions than Bristol-Myers Squibb/Imclone's Erbitux.
Amgen's Phase III Osteoporosis Study Is Company's Largest Clinical Program
Clinical trials for Amgen's bone loss therapy AMG 162 will look at the entire spectrum of bone health, VP-R&D Perlmutter says. Phase II studies demonstrated lower incidence of dyspepsia and more rapid absorption than Fosamax, he says.